Conatus Pharmaceuticals (NASDAQ:CNAT) released its earnings results on Wednesday, March 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.02, Bloomberg Earnings reports. The firm had revenue of $8.80 million during the quarter, compared to analyst estimates of $9.60 million. Conatus Pharmaceuticals had a negative net margin of 49.17% and a negative return on equity of 61.58%.
Shares of Conatus Pharmaceuticals (CNAT) traded down $0.38 during midday trading on Wednesday, reaching $6.54. 891,032 shares of the company traded hands, compared to its average volume of 764,409. Conatus Pharmaceuticals has a fifty-two week low of $3.88 and a fifty-two week high of $9.40. The firm has a market capitalization of $196.59, a price-to-earnings ratio of -10.72 and a beta of 1.28. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.82 and a quick ratio of 2.82.
An institutional investor recently bought a new position in Conatus Pharmaceuticals stock. California State Teachers Retirement System acquired a new stake in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 45,300 shares of the biotechnology company’s stock, valued at approximately $261,000. California State Teachers Retirement System owned 0.15% of Conatus Pharmaceuticals at the end of the most recent reporting period. 39.57% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Conatus Pharmaceuticals (CNAT) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS” was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://stocknewstimes.com/2018/03/14/conatus-pharmaceuticals-cnat-posts-quarterly-earnings-results-beats-expectations-by-0-02-eps.html.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.